Management of Hormone Receptor
Positive Metastatic Breast Cancer

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2017 Spring Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from June 15, 2017 to August 1, 2018

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.  To print or save your certificate, you will need to click on the “download” button and either print or save.

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This educational activity is supported by educational grants from
Novartis Pharmaceuticals and Pfizer

Death rates in breast cancer have been steadily decreasing over the past 20 years due to new and ever improving treatment options. However, once the disease progresses and distant metastases are present, a cure becomes less likely and few patients are rendered free of disease. Therapy in the advanced, metastatic setting then focuses on prolonging life and managing disease-and treatment-related adverse events. There is no single treatment strategy that will work for all patients with metastatic breast cancer (MBC). Instead, treatment selection must be individualized based upon patient- and tumor-specific factors, as well as safety and efficacy profile of available agents, with an emphasis on the combined goals of tumor control, prolonged survival, and maintenance of patient quality of life. With the advancement and complexity of different treatment options, clinicians are being challenged to quickly diagnose breast cancer and its corresponding stage, and provide the best evidenced-based treatment that is available for patients. Breast cancers that are hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative are the most common subtype of breast cancer. As the treatment landscape changes and new options become available to clinicians, it is becoming more difficult for healthcare professionals to stay up to date on the different options and strategies for patients with advanced breast cancer. In the last few years, new treatment options have been approved for patients with HR+ advanced breast cancer, especially in therapy beyond the first or second line setting.

Upon Completion of this activity, participants will be able to:

  • Review the efficacy, safety, and mechanisms of action of current and emerging therapies in the management hormone receptor-positive (HR+) advanced breast cancer

  • Analyze the role of mechanistic target of rapamycin (mTOR) inhibitors and cyclin-dependent kinase (CDK) 4/6 inhibitors in the management of HR+ advanced breast cancer

  • Identify the circumstances in which an mTOR inhibitor or a CDK 4/6 inhibitor would be an appropriate treatment option for a patient with HR+ advanced breast cancer

  • Discuss strategies for effectively managing adverse events and facilitating patient adherence to therapy in HR+ advanced breast cancer

  • Explore the implementation of a shared decision-making approach with patients who have HR+ advanced breast cancer to engage them in their care

Faculty: Adam M. Brufsky, MD, PhD, FACP
Professor of Medicine
University of Pittsburgh School of Medicine
Associate Division
Chief Division of Hematology/Oncology
University of Pittsburgh School of Medicine
Department of Medicine


Dr. Brufsky serves as a consultant to Lilly, Novartis and Pfizer. His presentation has been peer reviewed.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jacquelyn Smith, RN, BSN, MA, CMCN has no real or perceived financial relationships to disclose.
Katie Eads has no real or perceived financial relationships to disclose.
Will Williams has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

The National Association of Managed Care Physicians designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.  Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This educational activity is supported by educational grants from
Novartis Pharmaceuticals and Pfizer

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue